To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

For the quarter ended September 2025, Conmed (CNMD) reported revenue of $337.93 million, up 6.7% over the same period last year. EPS came in at $1.08, compared to $1.05 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $336.52 million, representing a surprise of +0.42%. The company delivered an EPS surprise of +2.86%, with the consensus EPS estimate being $1.05.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how t ...

Conmed (CNMD) came out with quarterly earnings of $1.08 per share, beating the Zacks Consensus Estimate of $1.05 per share. This compares to earnings of $1.05 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +2.86%. A quarter ago, it was expected that this medical technology company would post earnings of $1.13 per share when it actually produced earnings of $1.15, delivering a surprise of +1.77%.Over the last four quarters, th ...

CONMED (NYSE:CNMD) Q3 2025 Earnings Call November 05, 2025 04:30 PM ET Speaker1Good day and thank you for standing by. Welcome to ConMed's third quarter fiscal 2025 earnings conference call. At this time, all participants are in a listen only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, ...

Investor Presentation Q3 2025 Earnings Pat J. Beyer President and Chief Executive Officer Todd W. Garner Executive Vice President and Chief Financial Officer November 5, 2025 Forward-Looking Information This presentation may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward- looking statements herein or in previous disclosures ...

CONTACT: CONMED Corporation Todd W. Garner Chief Financial Officer ToddGarner@conmed.com CONMED Corporation Announces Third Quarter 2025 Financial Results Largo, Florida, November 5, 2025 – CONMED Corporation (NYSE: CNMD) today announced financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Highlights NEWS RELEASE "We are pleased with our third quarter performance, which reflects continued progress in strengthening our supply chain and strong execution across our core growth p ...

We came across a bullish thesis on CONMED Corporation on DeepValue Capital’s Substack. In this article, we will summarize the bulls’ thesis on CNMD. CONMED Corporation's share was trading at $46.00 as of September 26th. CNMD’s trailing P/E was 12.99 according to Yahoo Finance. 10 Most Competitive Medical Fellowships in America egyjanek/Shutterstock.com Conmed Corporation (CONMED) is a global medical device company focused on enabling less invasive and more effective surgery across orthopedics, general s ...

Zacks Premium服务概述 - 提供Zacks Rank和Zacks Industry Rank每日更新服务 帮助投资者提升投资决策能力 [1] - 包含Zacks第一排名清单全访问权限 股票筛选工具及股票研究报告资源 [1] - 整合Zacks风格评分系统作为核心分析工具 [1] Zacks风格评分系统构成 - 采用字母评级体系（A至F级）评估股票价值 增长和动量三大投资特性 [3] - 价值评分侧重市盈率 PEG比率 市销率及现金流倍数等估值指标 [3] - 增长评分关注企业财务健康度 历史及预测收益 销售额与现金流表现 [4] - 动量评分分析股价趋势 周度价格变化及盈利预期月度百分比调整 [5] - VGM评分综合三大风格评分 通过加权计算筛选兼具价值 增长与动量优势的股票 [6] 评分系统与Zacks排名协同机制 - Zacks排名依托盈利预测修正模型 1988年以来第一评级股票年均回报率达+23.75% [7] - 每日超200家公司获强力买入评级 另有600家维持买入评级 [8] - 建议优先选择Zacks排名第1-2级且风格评分达A-B级的股票 [9] - 即使风格评分优异 第4-5级评级股票因盈利预期下行仍存在股价下跌风险 [10] 案例企业Conmed(CNMD)分析 - 公司主营微创手术器械及监测设备制造 拥有3600名员工及多处生产基地 [11] - 当前Zacks排名为持有级 VGM风格评分获A级 [11] - 动量评分达B级 近四周股价上涨8.6% [12] - 过去60天内两名分析师上调2025财年盈利预测 共识预期上调0.04美元至每股4.46美元 [12] - 历史平均盈利惊喜度达+9.2% 兼具优势排名与评分特征 [12]

Zacks研究服务核心功能 - 提供Zacks评级和行业排名每日更新 Zacks第一评级名单 股票研究报告及高级选股工具 [1] - 包含Zacks风格评分系统作为核心分析工具 帮助投资者构建高胜率投资组合 [1][2] 风格评分系统构成 - 价值评分通过市盈率 PEG 市销率等比率识别被低估股票 [3] - 增长评分分析预测和历史收益 销售额及现金流寻找可持续增长标的 [4] - 动量评分利用周价格变动和月度盈利预期变化判断交易时机 [5] - VGM综合评分整合三大风格因子 采用加权计算方式 [6] 评分与评级协同机制 - Zacks评级基于盈利预期修正模型 第一评级股票自1988年来年均回报达23.75% [7] - 每日有超过200只强买入评级股票及600只买入评级股票 [8] - 建议优先选择同时具备第一/二评级和A/B风格评分的股票 [9] - 即使获得A/B评分 若评级为卖出/强卖出仍存在股价下跌风险 [10] 医疗器械公司Conmed案例 - 公司主营微创手术器械及监测设备 拥有3600名员工及多个生产基地 [11] - 当前获Zacks持有评级 VGM评分达到A级 [11] - 过去四周股价上涨4.8% 动量评分获A级 [12] - 60天内两名分析师上调2025财年盈利预期 共识预期上调0.04美元至每股4.46美元 [12] - 历史平均盈利惊喜度达+9.2% 兼具优质评级与高分风格评分 [12]

财务表现 - 第二季度调整后每股收益(EPS)为1.15美元 超出市场预期1.8% 同比增长17.3% [1] - 第二季度营收3.423亿美元 同比增长3.1% 超出市场预期0.8% 按固定汇率计算增长2.9% [2] - 调整后毛利润1.934亿美元 同比增长5.3% 毛利率提升120个基点至56.5% [6] - 运营收入4510万美元 同比增长13.3% 运营利润率提升110个基点至15.7% [6] - 期末现金余额3390万美元 较上季度减少160万美元 [7] 业务板块表现 - 骨科手术业务收入1.407亿美元 同比增长0.9% 美国市场下降0.8% 国际市场增长1.9% [3] - 普通外科业务收入2.016亿美元 同比增长4.7% 美国市场增长4.3% 国际市场增长5.7% [4] - 美国市场总销售额1.906亿美元 同比增长2.8% 国际市场销售额1.517亿美元 同比增长3.4% [5] 增长驱动因素 - 主要增长来自高增长产品领域(BioBrace AirSeal Foot & Ankle) [2] - AirSeal平台在机器人和腹腔镜手术中的采用率持续提升 [13] - Buffalo Filter业务实现两位数增长 受益于美国和国际市场对手术烟雾抽吸的法规要求 [13] - BioBrace和Foot & Ankle产品实现两位数增长 供应链中断情况有所缓解 [13] 2025年展望 - 上调全年营收指引至13.56-13.78亿美元(原指引13.50-13.78亿美元) [10] - 上调全年调整后EPS指引至4.40-4.55美元(原指引4.31-4.46美元) [11] - 预计2025年下半年关税影响为每股9美分 [11] - 第三季度营收指引3.30-3.37亿美元 EPS指引1.03-1.08美元 [11] - 长期目标维持中高个位数收入增长 重点发展AirSeal Buffalo Filter BioBrace和Foot & Ankle四大战略产品 [14] 运营优化 - 供应链转型成为战略资产 改善采购计划和生产流程 [14] - 运营效率提升抵消了关税带来的成本压力 维持毛利率指引 [15]